1. Home
  2. CANF vs GV Comparison

CANF vs GV Comparison

Compare CANF & GV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • GV
  • Stock Information
  • Founded
  • CANF 1994
  • GV 2013
  • Country
  • CANF Israel
  • GV Canada
  • Employees
  • CANF N/A
  • GV N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • GV Other Consumer Services
  • Sector
  • CANF Health Care
  • GV Real Estate
  • Exchange
  • CANF Nasdaq
  • GV Nasdaq
  • Market Cap
  • CANF 14.4M
  • GV 6.6M
  • IPO Year
  • CANF N/A
  • GV 2022
  • Fundamental
  • Price
  • CANF $2.46
  • GV $1.76
  • Analyst Decision
  • CANF Strong Buy
  • GV
  • Analyst Count
  • CANF 2
  • GV 0
  • Target Price
  • CANF $14.00
  • GV N/A
  • AVG Volume (30 Days)
  • CANF 135.4K
  • GV 99.7K
  • Earning Date
  • CANF 11-15-2024
  • GV 10-25-2024
  • Dividend Yield
  • CANF N/A
  • GV N/A
  • EPS Growth
  • CANF N/A
  • GV N/A
  • EPS
  • CANF N/A
  • GV 0.32
  • Revenue
  • CANF $667,000.00
  • GV $9,380,985.00
  • Revenue This Year
  • CANF $356.93
  • GV N/A
  • Revenue Next Year
  • CANF N/A
  • GV N/A
  • P/E Ratio
  • CANF N/A
  • GV $5.56
  • Revenue Growth
  • CANF N/A
  • GV 11.25
  • 52 Week Low
  • CANF $1.81
  • GV $1.52
  • 52 Week High
  • CANF $4.69
  • GV $8.85
  • Technical
  • Relative Strength Index (RSI)
  • CANF 62.91
  • GV 37.28
  • Support Level
  • CANF $1.87
  • GV $2.26
  • Resistance Level
  • CANF $2.55
  • GV $1.94
  • Average True Range (ATR)
  • CANF 0.17
  • GV 0.21
  • MACD
  • CANF 0.06
  • GV -0.09
  • Stochastic Oscillator
  • CANF 85.94
  • GV 7.72

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About GV Visionary Education Technology Holdings Group Inc.

Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.

Share on Social Networks: